- Supported exchanges /
- F /
- 2Q5.F
ENOCHIAN BIOSCI. DL-0001 (2Q5 F) stock market data APIs
Renovaro Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.
ENOCHIAN BIOSCI. DL-0001 Financial Data Overview
| 0.448 | |
| 0.448 | |
| - | |
| 0.474 | |
| 0.448 | |
| 0.335-4.44 | |
| 89 795 K | |
| 156 M | |
| 0 | |
| 0.553 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
ENOCHIAN BIOSCI. DL-0001 Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA -27 266 436
- Earnings Per Share -0.78
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get ENOCHIAN BIOSCI. DL-0001 Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get ENOCHIAN BIOSCI. DL-0001 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
